![Intra-Cellular Therapies, Inc. logo](/logos/ITCI.webp)
Intra-Cellular Therapies, Inc.
NASDAQ:ITCI
Overview | Financials
Company Name | Intra-Cellular Therapies, Inc. |
Symbol | ITCI |
Currency | USD |
Price | 73.54 |
Market Cap | 7,770,751,180 |
Dividend Yield | 0% |
52-week-range | 45.5 - 84.89 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Sharon Mates Ph.D. |
Website | https://www.intracellulartherapies.com |
An error occurred while fetching data.
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD